---
title: "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (688505.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688505.SH.md"
symbol: "688505.SH"
name: "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T18:36:50.921Z"
locales:
  - [en](https://longbridge.com/en/quote/688505.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688505.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688505.SH.md)
---

# Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (688505.SH)

## Company Overview

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.fd-zj.com](https://www.fd-zj.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: D (0.61)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 187 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -11.69% |  |
| Net Profit YoY | -480.49% |  |
| P/B Ratio | 3.83 |  |
| Dividend Ratio | 0.38% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8141180315.04 |  |
| Revenue | 656107288.55 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -6.88% | D |
| Profit Margin | -23.27% | E |
| Gross Margin | 91.76% | A |
| Revenue YoY | -11.69% | E |
| Net Profit YoY | -480.49% | E |
| Total Assets YoY | -7.30% | E |
| Net Assets YoY | -7.96% | D |
| Cash Flow Margin | -83.90% | E |
| OCF YoY | -11.69% | E |
| Turnover | 0.27 | D |
| Gearing Ratio | 9.47% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-11.69%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-480.49%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.83",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.38%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8141180315.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "656107288.55",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-6.88%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-23.27%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "91.76%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-11.69%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-480.49%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.30%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-7.96%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-83.90%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-11.69%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.27",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "9.47%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -52.65 | 203/215 | 270.20 | 230.60 | 219.99 |
| PB | 3.78 | 163/215 | 4.20 | 3.98 | 3.82 |
| PS (TTM) | 12.25 | 193/215 | 13.74 | 12.60 | 12.05 |
| Dividend Yield | 0.39% | 139/215 | 0.48% | 0.36% | 0.33% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688505.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688505.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688505.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**